Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension…

By Dr. Matthew Watson

– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile –

Davos Alzheimer’s Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer’s Disease Research in North Africa - April 23rd, 2025
Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala - April 23rd, 2025
Cambridge’s DIOSynVax and Singapore’s ACM Biolabs to Advance Pandemic-Ready Universal Bird Flu Vaccine with International Support - April 23rd, 2025
NewGen Filed 2024 Annual Report on Form 20-F - April 23rd, 2025
Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs - April 23rd, 2025
Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm - April 23rd, 2025
Elite Clinical Network and HealthyU Clinics Announce Strategic Partnership to Expand Access to Clinical Research - April 23rd, 2025
Andrew Taylor joins Novonesis’ Executive Leadership Team - April 23rd, 2025
Sirona Biochem Announces Debenture Financing - April 23rd, 2025
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors - April 23rd, 2025
Digicann Ventures Provides Update Regarding Proposed RTO Transaction - April 23rd, 2025
Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe... - April 23rd, 2025
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones - April 23rd, 2025
Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025 - April 23rd, 2025
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates - April 23rd, 2025
NurExone Appoints Biotech Industry Leader - Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into... - April 23rd, 2025
OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and... - April 23rd, 2025
Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS) - April 23rd, 2025
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 - April 23rd, 2025
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a... - April 23rd, 2025
Preliminary Results for the Year Ended 31 December 2024 - April 14th, 2025
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects - April 14th, 2025
Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements - April 14th, 2025
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study - April 14th, 2025
Scilex Holding Company Announces 1-for-35 Reverse Stock Split - April 14th, 2025
Nika Pharmaceuticals, Inc. (NIKA) Latest Developments - April 14th, 2025
TestoPrime Reviews: Best Testosterone Booster Supplement For Men Over 40 & 50 – Is TestoPrime Tablets Safe? - April 14th, 2025
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 14th, 2025
Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and... - April 14th, 2025
argenx Announces Annual General Meeting of Shareholders on May 27, 2025 - April 14th, 2025
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 14th, 2025
Organogenesis Supports CMS’ Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High... - April 14th, 2025
4DMT Announces New Employment Inducement Grants - April 14th, 2025
Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements - April 14th, 2025
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document - April 14th, 2025
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 14th, 2025
Kane Biotech Announces New Agreement with Outside the Box Capital Inc. - April 14th, 2025
Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the... - April 14th, 2025
European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy - April 14th, 2025
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US - April 14th, 2025
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates - March 31st, 2025
HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results - March 31st, 2025
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - March 31st, 2025
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors - March 31st, 2025
Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX - March 31st, 2025
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results - March 31st, 2025
HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress - March 31st, 2025
Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates - March 31st, 2025
Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery... - March 31st, 2025
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025 - March 31st, 2025
Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress - March 31st, 2025
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study - March 31st, 2025
First Three Children to Commence Treatment With Ryoncil® - March 31st, 2025
BioVersys Announces Important BV100 Patent Granted by Chinese Patent Office - March 31st, 2025
Opthea Announces Decision to Discontinue Wet AMD Trials - March 31st, 2025
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the... - March 31st, 2025
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA - March 31st, 2025
AAVantgarde and TIGEM Publish Groundbreaking Research in Science Advances - March 31st, 2025
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 - March 31st, 2025
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting - March 22nd, 2025
FDA Approves New Prostate Cancer Imaging Agent Gozellix® - March 22nd, 2025
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category - March 22nd, 2025
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test - March 22nd, 2025
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update - March 22nd, 2025
Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030 - March 22nd, 2025
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 - March 22nd, 2025
PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington - March 22nd, 2025
Bright Green Corporation Announces the next steps for the completion of its restructuring plan - March 22nd, 2025
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million - March 22nd, 2025
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones - March 22nd, 2025
Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX - March 22nd, 2025
Impact Biomedical Inc. Announcement Stock Activity/Pricing - March 22nd, 2025
I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - March 22nd, 2025
Better Choice Company Shareholders Overwhelmingly Approve Acquisition of SRx Health Solutions and Related Proposals - March 22nd, 2025
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results - March 22nd, 2025
Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting... - March 22nd, 2025
Atea Pharmaceuticals Issues Statement Regarding Director Nominations - March 22nd, 2025
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. - March 22nd, 2025
Arialief Reviews (Is It Safe And Legit To Use?) What Do Arialief Consumer Reports Say About Its Efficacy? - March 22nd, 2025
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of... - March 11th, 2025

Global News Feed commento

Comments Off | data

March 31st, 2025

About... Dr. Matthew Watson

This author published 6172 posts in this site.

Comments are closed.

Previous post - Next post

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension…

By Dr. Matthew Watson

About... Dr. Matthew Watson

Share

Comments are closed.

Categories

Archives

Recommended Sites